Collegium Pharmaceutical initiated a $50 million accelerated share repurchase agreement with Goldman Sachs on Thursday, immediately retiring a portion of its outstanding equity. The company received an initial delivery of shares at execution, with final settlement tied to volume-weighted average pricing over the repurchase period.
The specialty pharmaceutical company, which markets extended-release stimulant formulations including Jornay PM for ADHD treatment, authorized the program without expanding its existing board-approved buyback authorization. Collegium did not disclose what percentage of float the $50 million represents, but the company carried a market capitalization near $1.1 billion as of Wednesday's close. Premarket activity pushed shares higher by mid-single digits on the announcement.
The timing follows eighteen months of elevated demand across the ADHD therapeutic category, driven by widespread generic Adderall shortages that began in Q4 2022. Collegium benefited materially from patient switching and inventory restocking cycles through 2023, but faces normalization headwinds as Teva and other generics restore supply. Management has guided to flattening prescription trends in recent quarters. The ASR structure suggests leadership views current valuation as attractive relative to organic reinvestment opportunities, a common signal when growth deceleration is already reflected in the stock.
Accelerated share repurchases differ from open-market programs by delivering immediate share retirement and eliminating execution risk, though at a modest liquidity premium. Goldman Sachs borrows the shares, sells them into the market over the agreement term, and settles the final share count with Collegium based on realized pricing. The structure appeals to management teams seeking immediate EPS accretion and reduced float ahead of earnings events or activist pressure.
Allocators should track Collegium's prescription data through IQVIA weekly scripts and Symphony Health over the next sixty days to confirm whether branded stimulant demand stabilizes or continues to erode. The company reports Q1 2025 earnings in early May. If revenue guidance incorporates further volume declines, the buyback may represent tactical positioning rather than durable capital allocation policy. Generic Adderall availability remains the swing variable—Teva has restored approximately 60% of pre-shortage production capacity, with full normalization expected by mid-2025.
Goldman's involvement is procedural, not strategic. The bank earns a spread on borrowed shares and execution fees. Collegium retains roughly $180 million in cash and equivalents after the repurchase, sufficient to fund operations and service its $150 million term loan without covenant stress. The balance sheet remains uncomplicated.